|
TargetMol
tlr4 inhibitor ![]() Tlr4 Inhibitor, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/FDA-Approved+Kinase+Inhibitor+Library/pmc12866821-237-33-61 Average 94 stars, based on 1 article reviews
tlr4 inhibitor - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
targetmol 383 tyrosine kinase inhibitor library ![]() Targetmol 383 Tyrosine Kinase Inhibitor Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/Tyrosine+Kinase+Inhibitor+Library/ppr0939611-212-12-12 Average 93 stars, based on 1 article reviews
targetmol 383 tyrosine kinase inhibitor library - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
TargetMol
ga t6343 ![]() Ga T6343, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/Geldanamycin/pmc11651664-298-0-8 Average 97 stars, based on 1 article reviews
ga t6343 - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
TargetMol
mertk inhibition ![]() Mertk Inhibition, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/UNC2025/pmc11691640-196-1-4 Average 94 stars, based on 1 article reviews
mertk inhibition - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
selective vegfr3 tyrosine kinase inhibitor ![]() Selective Vegfr3 Tyrosine Kinase Inhibitor, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/Tyrosine+kinase+inhibitor/bio_rxiv__64898__2026__08__19__745806-64-2-10 Average 97 stars, based on 1 article reviews
selective vegfr3 tyrosine kinase inhibitor - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
TargetMol
targetmol library ![]() Targetmol Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/EGFR+vIII+Protein%2C+Human%2C+Recombinant+(His+%26+Avi)%2C+Biotinylated/bio_rxiv__2023__11__27__568880-272-0-0 Average 94 stars, based on 1 article reviews
targetmol library - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
alw ii 41 27 ![]() Alw Ii 41 27, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/ALW-II-41-27/pmc10092769-133-5-6 Average 91 stars, based on 1 article reviews
alw ii 41 27 - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
TargetMol
ros ![]() Ros, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/Anti-ROS1+Polyclonal+Antibody/pmc12445330-46-2-11 Average 93 stars, based on 1 article reviews
ros - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
TargetMol
tkis ![]() Tkis, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/Axitinib/10__1158_slash_2767___9764__crc___24___0304-28-0-11 Average 94 stars, based on 1 article reviews
tkis - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
baf3 flt3 itd cells ![]() Baf3 Flt3 Itd Cells, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/FLT3+Protein%2C+Human%2C+Recombinant/pmc11229190-70-5-36 Average 94 stars, based on 1 article reviews
baf3 flt3 itd cells - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
multitargeted receptor tyrosine kinase rtk inhibitor ![]() Multitargeted Receptor Tyrosine Kinase Rtk Inhibitor, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/Tyrosine/pm33955652-43-15-30 Average 97 stars, based on 1 article reviews
multitargeted receptor tyrosine kinase rtk inhibitor - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
TargetMol
human ddr1 ![]() Human Ddr1, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/targetmol+tyrosine+kinase+modulator+library/DDR1+Protein%2C+Human%2C+Recombinant/10__1016_slash_j__apsb__2026__03__041-107-14-11 Average 94 stars, based on 1 article reviews
human ddr1 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Advanced Science
Article Title: VDLIN: A Deep Learning‐Based Platform for Methylcobalamin‐Inspired Immunomodulatory Compound Screening
doi: 10.1002/advs.202413775
Figure Lengend Snippet: Co7 induces Ifnb1 expression via the TLR4 signaling pathway. A) Volcano plot illustrating the distribution of differentially expressed genes (DEGs) between the Co7 and DMSO treatment groups after 3 h in RAW 264.7 cells. Fold changes are presented as log 2 transformations. Red dots represent DEGs upregulated in the Co7 group. B) Protein‐protein interaction (PPI) network analysis of differentially expressed genes (DEGs) in the Co7‐treated group compared to the DMSO group, revealing significant enrichment in pathways associated with the innate immune response and type I interferon signaling. C) KEGG pathway enrichment analysis of DEGs induced by Co7, highlighting associations with innate immune response pathways. D) Co7 (50 µmol/L) exhibiting strong antiviral effects against VSV in RAW 264.7 and HT29 cells. E) Co7 significantly reduced the inflammatory response induced by LPS, VSV, EMCV, and HSV in RAW 264.7 cells. F) Volcano plot representing the differential gene expression analysis between Co7‐ and LPS‐treated RAW 264.7 cells after 3 h of treatment. Fold changes are displayed as log 2 transformations. Red dots indicate genes upregulated in the Co7 group, while blue dots represent downregulated genes compared to LPS treatment. G) Western blot analysis demonstrating that Co7 inhibited the expression of iNOS and COX2, as well as the phosphorylation of NF‐κB‐P65 at the protein level in RAW 264.7 cells. H) Co7 significantly reduced the mortality rate in mice (n = 10 per group) following LPS challenge (20 mg/kg), compared to the PBS control group. RT‐qPCR data were presented as means ± SEM from three independent experiments. Statistical significance was determined using one‐way ANOVA with Bonferroni's multiple comparisons test (left three panels in E), paired‐samples t‐test (D, right panel of EMCV and HSV in E), or the log‐rank test (H). * P < 0.05, ** P < 0.01, and *** P < 0.001.
Article Snippet: Each inhibitor was dissolved in anhydrous DMSO and diluted to its respective working concentration: C29 (10 μM, S6597, Selleck) served as a TLR2 inhibitor; Procyanidin B1 (30 μM, HY‐N0795, MedChemExpress) acted as a
Techniques: Expressing, Gene Expression, Western Blot, Phospho-proteomics, Control, Quantitative RT-PCR
Journal: Science Advances
Article Title: NLRP3 inflammasome constrains liver regeneration through impairing MerTK-mediated macrophage efferocytosis
doi: 10.1126/sciadv.adq5786
Figure Lengend Snippet: ( A ) ELISA analysis of serum IL-6 level ( n = 3 per group). ( B ) ELISA analysis of serum TNF-α level ( n = 3 per group). ( C and D ) Representative flow cytometry analysis plots and the quantification of Ly6C hi or Ly6C lo hepatic macrophages 36 hours after PHx ( n = 3 per group). ( E ) mRNA expression of Ly6C hi or Ly6C lo macrophage markers in isolated hepatic macrophages ( n = 3 per group). iNOS, inducible nitric oxide synthase; Arg-1, arginase-1. ( F ) RNA sequencing (RNA-seq) analysis of isolated hepatic macrophages 36 hours after PHx. Heatmap showed the proinflammatory (M1), reparative (M2), and efferocytosis gene expression profiles in Nlrp3 Δ mye mice and Nlrp3 fl/fl mice. ( G ) Bubble chart showing the top 20 of Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of the significant up-regulated genes in Nlrp3 Δ mye mice. PPAR, peroxisome proliferator–activated receptor. ( H and I ) mRNA expression of efferocytosis genes in isolated hepatic macrophages 36 hours after PHx ( n = 3 per group). ( J ) Representative fluorescent images and quantification of engulfing ACs (TUNEL) by hepatic macrophages (CD68) in situ from Nlrp3 Δ mye mice and Nlrp3 fl/fl mice 36 hours after PHx (scale bar, 50 μm) ( n = 5 per group). ( K ) Flow cytometry analysis of MerTK expression in isolated hepatic macrophages 36 hours after PHx ( n = 3 per group). ( L ) Representative fluorescent images and quantification of engulfing ACs (pHrodo labeled, green) by BMDMs (F-actin labeled, red) isolated from Nlrp3 Δ mye mice and Nlrp3 fl/fl mice (scale bar, 50 μm) ( n = 5 per group). ( M ) mRNA expression of MerTK and HGF in isolated hepatic macrophages after cocultured with ACs ( n = 3 per group). Data are shown as means ± SD. * P < 0.05; ** P < 0.01; *** P < 0.001. h, hours.
Article Snippet: For
Techniques: Enzyme-linked Immunosorbent Assay, Flow Cytometry, Expressing, Isolation, RNA Sequencing Assay, TUNEL Assay, In Situ, Labeling
Journal: Science Advances
Article Title: NLRP3 inflammasome constrains liver regeneration through impairing MerTK-mediated macrophage efferocytosis
doi: 10.1126/sciadv.adq5786
Figure Lengend Snippet: The NLRP3 inflammasome exhibited robust activation in macrophages during the initial phase of liver regeneration following 70% PHx. Blocking macrophage NLRP3 significantly enhanced liver regeneration, whereas overexpression of NLRP3 impaired it after PHx. Deficiency in Nlrp3 promoted MerTK-mediated efferocytosis, thereby inducing a pro-reparative Ly6C lo phenotype in macrophages. This image was drawn by the authors.
Article Snippet: For
Techniques: Activation Assay, Blocking Assay, Over Expression
Journal: International Journal of Biological Sciences
Article Title: Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer
doi: 10.7150/ijbs.82567
Figure Lengend Snippet: Inhibiting EphA2 phosphorylation by ALW-II-41-27 impedes BLBC cell stemness and chemoresistance. (A-B) Detection of sphere formation by mamosphere formation assay after treating HCC1937 cells with chemotherapeutic drugs PTX (2 μM) and DDP (2 μM) alone or in combination with ALW-II-41-27 (50 nM) for 48 h. Scale bar=250 μm. (C-D) Detection of the ALDH + cell ratio by flow cytometry after treatment of HCC1937 and HCC1806 cells with the chemotherapeutic agents PTX (2 μM) or DDP (2 μM) alone or in combination with ALW-II-41-27 (50 nM) for 48 h; (E-F) Detection of EphA2 and EphA2 pS897 expression by WB after treatment of HCC1937 and HCC1806 cells with the chemotherapeutic agents PTX (2 μM) or DDP (2 μM) alone or in combination with ALW-II-41-27 (50 nM) for 48 h; (G-H) IC50 assay in HCC1937 and HCC1806 cells treated with chemotherapeutic agents PTX or DDP alone or in combination with ALW-II-41-27. Changed folds in (E) and (F) of indicated proteins were referenced to DMSO, normalized to GAPDH, respectively.
Article Snippet: Drugs and cell factors included
Techniques: Phospho-proteomics, Tube Formation Assay, Flow Cytometry, Expressing
Journal: International Journal of Biological Sciences
Article Title: Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer
doi: 10.7150/ijbs.82567
Figure Lengend Snippet: EphA2 pS897 contributes to BLBC cell chemoresistance and indicates the NCT response. (A) Detection of EphA2, KLF5 and EphA2 pS897 expression by WB after knocking down KLF5 in HCC1937 and HCC1806 cells while overexpressing EphA2 WT or EphA2 S897A and adding TNF-α(10 ng/mL) and ALW-II-41-27 (ALW; 50 nM); (B-E) Detection of the proliferation of HCC1806 and HCC1937 cells under PTX (B-C) or DDP (D-E) treatment. (F) EphA2 expression in samples from BLBC patients (BCIP database) with pCR and residual disease (RD) post neoadjuvant chemotherapy (NCT). (G) IHC detection of EphA2 pS897 expression in neoadjuvant chemoresistant (Group 1, N=11) and sensitive (Group 2, N=19) breast cancer tissue samples; (H-I) Statistics of IOD score (H) and pathological grading (I) for samples from (G). * or ns indicates the significance between the two and # indicates the significance between any one of each groups.
Article Snippet: Drugs and cell factors included
Techniques: Expressing
Journal: International Journal of Biological Sciences
Article Title: Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer
doi: 10.7150/ijbs.82567
Figure Lengend Snippet: ALW-II-41-27 enhanced the in vivo effect of chemotherapy against BLBC tumors. (A) Measurement of changes in the size of the tumor in different groups of treatment in vivo after treatment with chemotherapeutic agents PTX (1 mg/kg) or DDP (1 mg/kg), alone or in combination with ALW-II-41-27 (1 mg/kg); (B) Display of tumor tissues removed at the endpoint of control or drug treatment (day 24); (C) Statistics for weight of all tumor tissues; (D) Body weight of nude mice in each group; (E) Schematic representation of the scientific hypothesis that the inflammatory factor TNF-α promotes BLBC cell stemness by activating KLF5-EphA2 axis expression and thereby promoting pS897 EphA2-mediated chemoresistance; EphA2 inhibitor ALW-II-41-27 inhibits BLBC cell stemness and enhances chemotherapeutic drug sensitivity of BLBC cells, indicating that the membrane protein EphA2 is a potential therapeutic target for BLBC. * or ns indicates the significance between Viechle group and other individual group, and # indicates the significance between single drug groups (PTX, DDP, or ALW) with combined-drugs groups (DDP+ALW, or PTX+ALW).
Article Snippet: Drugs and cell factors included
Techniques: In Vivo, Control, Expressing, Membrane
Journal: Cell Communication and Signaling : CCS
Article Title: Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
doi: 10.1186/s12964-024-01729-0
Figure Lengend Snippet: Ningetinib significantly inhibits the activities of FLT3-ITD AML cells. A. Dose‒response curves for the FLT3-WT and FLT3-ITD (MV4-11 and MOLM13) AML cell lines after treatment with ningetinib for 48 h. The mean viability of triplicate at concentration 0 was normalized as 100% as control. The data are representative of three experiments. B. IC 50 values for ningetinib for the FLT3-WT (K562, HL60, OCI-AML2, OCI-AML3, U937, and THP-1) and FLT3-ITD (MV4-11 and MOLM13) AML cell lines. C, D. Proportion of apoptotic cells among the MV4-11 and MOLM13 cells treated with different concentrations of ningetinib for 48 h. E, F. Expression of PARP1, caspase 8, cleaved PARP1 and cleaved caspase 8 in MV4-11 and MOLM13 cells as analyzed by western blot after 48 h of treatment with different concentrations of ningetinib. G, H. Percentage of cells in different cell cycle phases detected by flow cytometry after treating cells with DMSO or 3 nM ningetinib for 24 h. I. Dose‒response curves for Ba/F3 and Ba/F3-FLT3-ITD cells treated with ningetinib for 48 h. The mean viability of triplicate at concentration 0 was normalized as 100% as control. The data are representative of three experiments
Article Snippet: Briefly, 1 × 10 7
Techniques: Concentration Assay, Control, Expressing, Western Blot, Flow Cytometry
Journal: Cell Communication and Signaling : CCS
Article Title: Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
doi: 10.1186/s12964-024-01729-0
Figure Lengend Snippet: Ningetinib inhibits FLT3 phosphorylation and exhibits antitumor activity against FLT3-ITD mutation in vivo. A, B, C. Western blot analysis of p-FLT3, FLT3, p-STAT5, STAT5, p-AKT, AKT, p-ERK and ERK in the MV4-11 and MOLM13 cells after treatment with ningetinib at the indicated doses for 2 h or 6 h. D. Schematic representation of the leukemic mouse model induced by Ba/F3-FLT3-ITD cells. E. Schematic representation of xenograft experiments using human MOLM13 cells. F. Proportion of GFP-positive cells in the BM and SP of mice, measured by flow cytometry on Day 12 ( n = 3 mice per group). G. The survival curves of BaF3-FLT3-ITD-diseased mice treated with the vehicle ( n = 7), ningetinib ( n = 7), gilteritinib ( n = 7) or quizartinib ( n = 7). H. The percentage of human CD45 positive cells in BM and SP of MOLM13-diseased NSG mice detected by flow cytometry on day 22 ( n = 3 mice per group). Error bars indicate mean ± standard error, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
Article Snippet: Briefly, 1 × 10 7
Techniques: Phospho-proteomics, Activity Assay, Mutagenesis, In Vivo, Western Blot, Flow Cytometry
Journal: Cell Communication and Signaling : CCS
Article Title: Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
doi: 10.1186/s12964-024-01729-0
Figure Lengend Snippet: The binding of ningetinib to FLT3. A. Overview of the docking results for ningetinib and FLT3 (Protein Data Bank: 6JQR) from two orthogonal views. B. Detailed docking sites for the binding of ningetinib and FLT3. Proteins are shown as cartoons, active pockets are shown as surfaces, green sticks are interacting amino acid residues, white sticks are small molecules, and orange dashed lines are hydrogen bonds. C. Ba/F3-FLT3-ITD cells were treated with ningetinib (10 µM) or DMSO for 1 h. The temperature ranged from 37 to 55 °C for testing. D. Proteins were quantified using ImageJ, and melting curves for FLT3 were plotted. The data are presented as means ± standard errors from three independent experiments
Article Snippet: Briefly, 1 × 10 7
Techniques: Binding Assay
Journal: Cell Communication and Signaling : CCS
Article Title: Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
doi: 10.1186/s12964-024-01729-0
Figure Lengend Snippet: Ningetinib inhibits secondary resistant TKD mutations in vitro. A. Dose‒response curve for cells with secondary mutations (FLT3-ITD-D835Y/D835V/Y842C/N676D/F691L) after treatment with ningetinib for 48 h. The mean viability of triplicate at concentration 0 was normalized as 100% as control. Error bars indicate the mean ± standard error, n = 3 independent experiments. B, C, D, E. Western blot analysis of p-FLT3, FLT3, p-STAT5, STAT5, p-AKT, AKT, p-ERK and ERK expression in the FLT3-ITD-D835Y/D835V/Y842C/F691L cells treated with ningetinib for 6 h. Tubulin was used as a loading control
Article Snippet: Briefly, 1 × 10 7
Techniques: In Vitro, Concentration Assay, Control, Western Blot, Expressing
Journal: Cell Communication and Signaling : CCS
Article Title: Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
doi: 10.1186/s12964-024-01729-0
Figure Lengend Snippet: Ningetinib exerts efficient inhibitory effects on FLT3-ITD-F691L mutations in vivo. A. Schematic representation of the mouse model of leukemia induced by Ba/F3-FLT3-ITD-F691L cells. B. Percentage of GFP-positive cells in PB of BALB/c mice, measured by flow cytometry on Day 10 ( n = 6 mice per group). C, D. Proportions of GFP-positive cells in BM and SP of BALB/c mice, examined by euthanizing 3 mice per group on Day 12. E. Weights of the spleens of the sacrificed mice in C ( n = 3 per group). F. Images of the spleens of sacrificed mice in E. G Images of the H&E-stained mouse livers and spleens. H. Survival curves for BaF3-FLT3-ITD-F691L diseased mice treated with the vehicle ( n = 6), ningetinib ( n = 6), gilteritinib ( n = 6) or quizartinib ( n = 6). I. Schematic representation of xenograft experiments using human MOLM13-FLT3-ITD-F691L cells. J. The percentage of human CD45 positive cells in BM and SP of MOLM13-FLT3-ITD-F691L diseased NSG mice detected by flow cytometry on day 22 ( n = 3 mice per group). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
Article Snippet: Briefly, 1 × 10 7
Techniques: In Vivo, Flow Cytometry, Staining
Journal: Cell Communication and Signaling : CCS
Article Title: Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
doi: 10.1186/s12964-024-01729-0
Figure Lengend Snippet: Ningetinib exhibits therapeutic potential in primary cells derived from patients with FLT3-ITD mutations. A, B, C, D. Cell viability values for primary BM cells from AML patients with FLT-ITD or FLT3-WT after treatment with different concentrations of ningetinib. The data are representative of three experiments. E. Cell viability values for PBMCs from healthy donors after treatment with different concentrations of ningetinib. F, G. Primary cells from FLT3-ITD-positive AML patients were cultured with ningetinib for 12 h. Proteins were extracted, and the expression of p-FLT3, FLT3, p-STAT5, STAT5, p-AKT, AKT, p-ERK and ERK was assessed by western blot analysis. Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
Article Snippet: Briefly, 1 × 10 7
Techniques: Derivative Assay, Cell Culture, Expressing, Western Blot